Most Recent
The Australian Competition and Consumer Commission will not oppose Google's $7.6 billion bid for cybersecurity firm Mandiant, the second-largest acquisition in the company's history.
Two former executives at Fuji Xerox's Australian unit have settled a lawsuit over their roles in a $450 million accounting scandal that has also ensnared auditor Ernst & Young.
Australian Mines has agreed to pay a $450,000 penalty to settle proceedings brought by ASIC after its managing director was allegedly caught lying at an investment conference about the value of an offtake agreement and funding for a project at its cobalt and nickel mine in Queensland.
A Globaltech patent for mining survey tools is facing another test, with rival technology company Reflex Technologies lodging an appeal after its invalidity challenge flopped.
Canada-based software company Dye & Durham has offered to divest its Australian business to win the ACCC's blessing for its proposed $2.9 billion acquisition of technology services provider Link Group.
A Melbourne-based clerking service has denied that it fired a clerk because she asked to work from home to manage her disability and was absent from work due to COVID-19 complications.
Telstra has agreed to deregister 162 radiocommunications sites after the ACCC expressed concerns the acquisition could stymie competition by hampering the rollout of Optus' 5G network.
The lead auditor for Big Un's flawed 2017 independent audit, which overstated the failed video company's cash and cash equivalents by $8.2 million, has been convicted of failing to comply with auditing standards following an investigation by ASIC.
The NSW Independent Commission has found that pork barrelling, in which a minister directs public funds for partisan political purposes, could sometimes amount to criminal corruption and has called for better regulation of grants funding.
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.